THE LEADING RESEARCH REPORTS DISTRIBUTION
NETWORK

icrowd research icrowd research icrowd research icrowd research icrowd research icrowd research icrowd research icrowd research

The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others

Jun 11, 2021 1:00 PM ET

The LAG-3-Next Generation Immunotherapy Market Size is projected to reach USD 7,009 Million by 2035, estimates DelveInsight | MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, and Others

Lag-3-Market-Insights

DelveInsight’s LAG-3-Next Generation Immunotherapy Market report also offers comprehensive insights into LAG-3-Next Generation Immunotherapy market size, trends, emerging therapies, technological innovations, market barriers, market drivers, ongoing LAG-3-Next Generation Immunotherapy clinical trials, key pharmaceutical companies, collaboration in the space, and actively pushing the growth of LAG-3-Next Generation Immunotherapy market size forward in the 7MM [US, EU5(France, Germany, the United Kingdom, Spain, and Italy) and Japan].

Key facts of the LAG-3-Next Generation Immunotherapy Market Report are:

  • According to Delveinsight, the market is anticipated to show positive growth due to the launch of upcoming therapies in the LAG-3 Next Generation target during the forecast period 2022–2035. Moreover, the US will occupy the maximum market share in the overall market size in 2035.
  • According to Delveinsight’s analysis, Among all LAG-3 target indications, NSCLC will occupy a significant market share of 98.81% by 2035. 
  • The total LAG-3 Market Size by indications is expected to be USD 3,421 Million by 2035.
  • According to Delveinsight’s analysis, the market is expected to show positive growth due to the launch of potential upcoming therapies in the LAG-3 target during the forecast period (2022–2035).
  • Currently, numerous trials are undergoing different indications for the LAG-3 target. Some of the major indications anticipated to show a better outcome by the launch of novel drugs include Breast Cancer, NSCLC, Gastric, Gastroesophageal Junction Cancer, Melanoma, Colorectal Cancer, Head and Neck Cancer, Multiple Myeloma.
  • The emerging trend in LAG3 Next-generation Immunotherapies with continuous headway movement along with new emerging technologies for the development of targeted therapies augurs the hopes for better therapeutic alternatives.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/lag-3-next-generation-immunotherapy-competitive-landscape

Some of LAG-3-Next Generation Immunotherapy Companies are:

  • MacroGenics
  • Novartis
  • Bristol-Myers Squibb
  • Merck
  • Immutep
  • Regeneron
  • Xencor
  • Incyte Biosciences
  • Agenus
  • F-star Therapeutics
  • And Many Others

Cancer immunotherapy and tumor microenvironment have been at the forefront of research over the past decades. Targeting immune checkpoints, especially programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1), has made a breakthrough in treating advanced malignancies. However, the low response rate brings a daunting challenge, changing the focus to dig deeply into the tumor microenvironment for alternative therapeutic targets. Strikingly, the inhibitory immune checkpoint Lymphocyte Activation Gene-3 (LAG-3) holds considerable potential.

LAG-3 suppresses T-cells activation and cytokine secretion, thereby ensuring immune homeostasis. It exerts differential inhibitory impacts on various types of lymphocytes and shows a remarkable synergy with PD-1 to inhibit immune responses. Targeting LAG-3 immunotherapy is moving forward in active clinical trials, and combination immunotherapy of anti-LAG-3 and anti-PD-1 has shown exciting efficacy in fighting PD-1 resistance.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/lag-3-next-generation-immunotherapy-competitive-landscape

Some of LAG-3-Next Generation Immunotherapy Drugs are:

  • MGD013
  • LAG525
  • Relatlimab
  • MK-4280
  • Eftilagimod Alpha
  • INCAGN2385
  • FS118
  • REGN3767
  • XmAb22841
  • And Many Others

Request for Free Sample Report: https://www.delveinsight.com/sample-request/lag-3-next-generation-immunotherapy-competitive-landscape

Scope of the LAG-3-Next Generation Immunotherapy Market Insight Report 

  • Geography Covered: The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Study Period: 3-year historical and 10-year forecasted analysis (2020-2035).
  • Key LAG-3-Next Generation Immunotherapy Companies: MacroGenics, Novartis, Bristol-Myers Squibb, Merck, Immutep, Regeneron, Xencor, and others.
  • Case Studies
  • KOL’s Views
  • Analyst’s View

Learn more about the report offerings @ LAG-3-Next Generation Immunotherapy Market Outlook

Latest Blogs:

Facts To Know About TNBC In The Breast Cancer Awareness Month

7 Most Common Myths: About Breast Cancer

Multiple Myeloma: An Incurable B-cell malignancy and A Vicious Cycle of Relapse

Breast Cancer: Understand your breasts, recognize the symptoms.

Related Market Reports:

Her2 Negative Breast Cancer Market Insight

DelveInsight’s “Her2 Negative Breast Cancer Market Insights, Epidemiology and Market Forecast 2030″ report will provide deep insight into Her2 Negative Breast Cancer Market, Epidemiological and Therapeutics market domain with a particular focus on key companies such as Eisai, Genetech, G1 Therapeutics, Roche, Sanofi, AstraZeneca, and others.

Her2 Positive Breast Cancer Market Insight

DelveInsight’s ‘Her2 Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast-2030’ report will provide deep insight into Her2 Positive Breast Cancer Market, Epidemiological and Therapeutics market domain with a particular focus on key companies such as Roche, Puma Biotechnology, Seattle Genetics, MacroGenics, Prestige Biopharma, EirGenix, Roche, Genentech, Pfizer, Merck, Eli Lilly, Horizon Pharma, Kadcyla, Genentech, Novartis, and several others.

Metastatic Triple-Negative Breast Cancer Market

DelveInsight’s “Metastatic Triple-Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2030” report will provide deep insight into Metastatic Triple-Negative Breast Cancer Market, Epidemiological and Therapeutics market domain with a particular focus on key companies such as Immunomedics, Merck, Pfizer, Astellas, Roche, Tesaro, AstraZeneca, Cytodyn and several others.

Non-Small Cell Lung Cancer Market

DelveInsight’s “Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast- 2030″ report will provide Non-Small Cell Lung Cancer Market, Epidemiological and Therapeutics market domain with a particular focus on key companies such as Novartis Pharmaceuticals, AbbVie, Xcovery, Janssen Pharmaceuticals, Merck and several others.

Multiple Myeloma Market

DelveInsight’s “Multiple Myeloma Market Insights, Epidemiology, and Market Forecast-2030″ report will provide Multiple Myeloma Market, Epidemiological and Therapeutics market domain with a particular focus on key companies such as AbbVie, Roche, Adaptimmune Therapeutics, GlaxoSmithKline, Merck Sharp & Dohme Corp, Amgen, AstraZeneca, and others.

Some of Newly Launched Report: 

About Delveinsight : 

DelveInsight Business Research is a leading Market Research and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.

Connect With Us at: LinkedIn | Facebook | Twitter